These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 19109802

  • 1. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
    Stockl KM, Le L, Zhang S, Harada AS.
    Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
    [Abstract] [Full Text] [Related]

  • 2. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [Abstract] [Full Text] [Related]

  • 3. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.
    Koro CE, Sowell MO, Stender M, Qizilbash N.
    Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791
    [Abstract] [Full Text] [Related]

  • 4. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [Abstract] [Full Text] [Related]

  • 5. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents.
    Koro C, Barrett S, Qizilbash N.
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):485-92. PubMed ID: 17192841
    [Abstract] [Full Text] [Related]

  • 6. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
    Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD.
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
    [Abstract] [Full Text] [Related]

  • 7. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR, Cha R, Brown MB, Jaber LA.
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [Abstract] [Full Text] [Related]

  • 8. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes.
    Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S.
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1065-71. PubMed ID: 17674425
    [Abstract] [Full Text] [Related]

  • 9. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY.
    Cerebrovasc Dis; 2013 Oct; 36(2):145-51. PubMed ID: 24029780
    [Abstract] [Full Text] [Related]

  • 10. A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006.
    Casscells SW, Granger E, Swedorske J, Goldhammer R, Shaheen M, Dorris J, Hong A, Wiktor M.
    Am J Ther; 2008 Oct; 15(3):198-205. PubMed ID: 18496256
    [Abstract] [Full Text] [Related]

  • 11. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
    Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT.
    Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
    [Abstract] [Full Text] [Related]

  • 12. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance.
    Durbin RJ.
    Diabetes Obes Metab; 2004 Jul; 6(4):280-5. PubMed ID: 15171752
    [Abstract] [Full Text] [Related]

  • 13. Use of thiazolidinediones and fracture risk.
    Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR.
    Arch Intern Med; 2008 Apr 28; 168(8):820-5. PubMed ID: 18443256
    [Abstract] [Full Text] [Related]

  • 14. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R, Arondekar BV, Camacho FT, Shenolikar RA, Horblyuk R, Anderson RT.
    Clin Ther; 2007 Jun 28; 29(6 Pt 1):1306-15. PubMed ID: 18036392
    [Abstract] [Full Text] [Related]

  • 15. Coronary heart disease outcomes in patients receiving antidiabetic agents.
    McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.
    Pharmacoepidemiol Drug Saf; 2007 Jul 28; 16(7):711-25. PubMed ID: 17551989
    [Abstract] [Full Text] [Related]

  • 16. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U, Pop-Busui R, Eagle KA.
    Ann Pharmacother; 2008 Oct 28; 42(10):1466-74. PubMed ID: 18698014
    [Abstract] [Full Text] [Related]

  • 17. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
    Hartung DM, Touchette DR, Bultemeier NC, Haxby DG.
    Pharmacotherapy; 2005 Oct 28; 25(10):1329-36. PubMed ID: 16185176
    [Abstract] [Full Text] [Related]

  • 18. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study.
    Brauchli YB, Jick SS, Curtin F, Meier CR.
    J Am Acad Dermatol; 2008 Mar 28; 58(3):421-9. PubMed ID: 18194825
    [Abstract] [Full Text] [Related]

  • 19. Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.
    Hurren KM, Taylor TN, Jaber LA.
    Diabetes Res Clin Pract; 2011 Jul 28; 93(1):49-55. PubMed ID: 21440324
    [Abstract] [Full Text] [Related]

  • 20. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
    Aquilante CL, Zhang W, McCollum M.
    Curr Med Res Opin; 2007 Mar 28; 23(3):489-94. PubMed ID: 17355730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.